PER-066-20尚未招募未知
A PHASE 1B/2 CLINICAL STUDY OF INTRATUMORAL ADMINISTRATION OF V937 IN COMBINATION WITH PEMBROLIZUMAB (MK-3475) IN PARTICIPANTS WITH ADVANCED/METASTATIC SOLID TUMORS
Merck Sharp & Dohme Corp., una subsidiaria de Merck & Co. Inc.,0 个研究点目标入组 2 人开始时间: 2020年10月22日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 2
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Has locally-advanced disease that is not amenable to surgery or radiation, or Stage IV advanced/metastatic solid tumor malignancies
- •2. Has histologically- or cytologically-confirmed diagnosis of an advanced/metastatic solid
- •3. Has measurable disease by RECIST 1.1 criteria as assessed by investigator. Target lesions in a previously irradiated area will be considered measurable if progression has been demonstrated in such lesions
- •4. Has submitted a baseline tumor sample for analysis (either de novo biopsy or an archival tumor block).
- •5. Has a performance status of 0 or 1 on the ECOG Performance Scale obtained within 72 hours prior to the first dose of study intervention
- •6. If participants have known HIV-positive disease, participants must have well-controlled HIV on ART
- •7. Demonstrate adequate organ function as defined in Table 7 (Refer to the Protocol)
- •8. Is male or female, from ≥18 years of age inclusive, at the time of signing the informed consent
- •9. Male participants are eligible to participate if they agree to the following during the intervention period for and for at least 120 days after the last dose of study intervention (Refer to the Protocol)
- •10. A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies (Refer to the Protocol)
- •11. The participant (or legally acceptable representative) provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research
- •12. Arm 1: Have at least one injectable lesion amenable to injection and/or biopsy.
- •13. Cohort A: Has locally recurrent, inoperable OR metastatic breast cancer treated with no more than 2 prior lines of therapy with skin involvement and/or subcutaneous lesions or accessible lymph nodes amenable to local injection
- •14. Cohort A: Has diagnosis of triple-negative breast cancer (estrogen receptor, progesterone receptor, and HER2-receptor negative status).
- •15. Cohort A: Has been treated with (neo)adjuvant anthracycline (unless anthracycline was contraindicated based on treating physician’s medical judgment)
- •16. Cohort B: Has histologically confirmed advanced or metastatic HNSCC of the oral cavity, oropharynx, hypopharynx, and/or larynx considered incurable and/or treated with no more than 1 previous line of therapy
- •17. Cohort B: Tumors must be PD-L1+ (CPS ≥1%)
- •18. Cohort B: Has documentation of HPV status for oropharyngeal cancers only. If HPV status has been previously determined, no retesting is required
- •19. Cohort C: Has histologically confirmed cSCC as the primary site of malignancy (metastatic skin involvement from another primary cancer or from cancers of unknown primary are not eligible).
- •20. Cohort C: Recurrent/metastatic disease only: Has metastatic disease defined as disseminated disease distant from the initial/primary site of diagnosis and/or with a history of locally-recurrent disease previously treated with surgery and/or radiotherapy, which is now incurable
- •21. Cohort C: Locally-advanced disease only: Participants ineligible for surgical resection. Contraindications to surgery are defined as:
- •22. Cohort C: Locally-advanced disease only: Received prior XRT to the index site or deemed ineligibl
排除标准
- •1. Has had chemotherapy, definitive radiation, or biological cancer therapy within 4 weeks (2 weeks for palliative radiation) prior to first dose of study intervention, or has not recovered to CTCAE Grade 1 or better
- •2. If major or minor surgery was performed at/near the area being considered for injection, participant must be recovered from toxicity and/or complications of intervention.
- •3. Has had injection, or radiation therapy of >30 Gy, participant must be recovered from toxicity and/or complications of intervention.
- •4. Has a history of second malignancy, unless potentially curative treatment has been completed with no further evidence of malignancy
- •5. Has known active CNS metastases and/or carcinomatous meningitis. Participants with treated brain metastases may participate if lesions are radiologically stable.
- •6. Has an active infection requiring therapy (exceptions: HIV criteria outlined in Section 5.1.1 and HBV and HCV criteria for HCC cohort as stated in Section 5.1.4.1 of the protocol)
- •7. Has a history of interstitial lung dis
- •8. Has a history of noninfectious pneumonitis requiring active steroid therapy or ongoing pneumonitis
- •9.Has an active autoimmune disease that required systemic treatment in the past 2 years (ie, necessitating use of disease modifying agents, corticosteroids, or immunosuppressive drugs) except vitiligo or resolved childhood asthma/atopy. Replacement therapy such as thyroxine, insulin, or physiologic corticosteroid replacement therapy (steroid use ≤10 mg prednisone, or its equivalent, daily) is not considered a form of systemic treatment and is allowed. The use of non-systemic steroids is permitted
- •10.Participants with known Hepatitis B or C infections or known to be positive for HBsAg/HBV DNA or Hepatitis C Antibody or RNA. Active Hepatitis C is defined by a known positive Hep C Ab result and known quantitative HCV RNA results greater than the lower limits of detection of the assay.
- •11.Participants with a history of Kaposi’s sarcoma and/or Multicentric Castleman’s Disease.
- •12.Has known hypersensitivity to V937 and/or pembrolizumab or any of their excipients
- •13.Has known psychiatric or substance abuse disorder that significantly interferes with cooperation with requirements of the trial
- •14.Has received prior therapy with anti-PD-1/PD-L1 agents, T-VEC or any other oncolytic virus therapies
- •15.Has received a live vaccine within 30 days prior to first dose of study drug. Examples of live vaccines include, but are not limited to: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, BCG, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are permitted. However, intranasal influenza (eg, FluMist®) and OPV vaccines are live attenuated vaccines and not permitted
- •16.Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention
- •17.Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study intervention
- •18.Has had esophageal or gastric variceal bleeding within the last 6 months. All participants should undergo screening for esophageal varices, unless such screening has been performed in t
研究者
相似试验
进行中（未招募）
1 期
Phase 1b/2 Study of V937 Injected into Tumors in Combination with Intravenous (IV) PembrolizumabAdvanced/metastatic solid tumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2020-001908-42-PLMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc185
进行中（未招募）
1 期
Phase 1b/2 Study of V937 Injected into Tumors in Combination with Intravenous (IV) PembrolizumabEUCTR2020-001908-42-PTMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc185
进行中（未招募）
1 期
Phase 1b/2 Study of V937 Injected into Tumors in Combination with Intravenous (IV) PembrolizumabEUCTR2020-001908-42-ITMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.185
已完成
1 期
Phase 1b/2 Study of ITu V937 in Combination with PembrolizumabJPRN-jRCT2033200191ohata Nijiro185
进行中（未招募）
1 期
Phase 1b/2 Study of V937 Injected into Tumors in Combination with Intravenous (IV) PembrolizumabAdvanced/metastatic solid tumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2020-001908-42-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc185